CD44 and hepatocellular carcinoma: In addition, cotreatment with sorafenib and Hedgehog signaling inhibitors had a dramatic synergistic effect of inhibiting the proliferation of HCC cells, especially CD44-positive cells, both in vitro and in vivo.